Option chain shows key data for Azure Power Global's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Azure Power Global.

Azure Power Global (OTC:AZREF) Stock, Option Chain

Azure Power Global Ltd produces and sells solar power in India. It is engaged in the development, construction, ownership, operation, maintenance, and management of solar power plants and the generation of solar energy. The company generates revenue from a mix of Indian central and state government utilities and commercial entities. Out of total operational capacity, approximately 90% of the company's plants are in high irradiation zones like Rajasthan, Gujarat, Maharashtra, and Andhra Pradesh. The Company has a single operating and reporting segment: Sale of power.

AZURE POWER GLOBAL LTD by Azure Power Global Limited

Azure Power Global Ltd

To improve financial condition and liquidity position, it is attempting to raise additional capital and working to implement cost-cutting measures, including additional reductions in operating expenses, negotiating terminations of long-term real estate leases, and attempting to reach a settlement covering all U.S. customers affected by the cyber incident as well as to resolve non-U.S. litigation and ongoing investigations from various governmental agencies arising from the cyber incident.

News

Guidance

23andMe Notes Continued Concerns Regarding Liquidity, Consideration Of Potential Ways To Address Operational And Financial Challenges

Barclays analyst Christine Cho maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Equal-Weight and lowers the price target from $18 to $15.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Sunrun, Lowers Price Target to $15

Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven.

NPCE

NeuroPace Expects FY25 Revenue Of $92M – $96M (Est $91.239M), Gross Margin Of 73% – 75%

HEES

United Rentals Commences Previously Announced Cash Tender Offer To Purchase H&E Equipment Services For $92.00 Per Share

23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) reported quarterly losses of $(1.02) per share. The company reported quarterly sales of $60.26 million which missed the analyst consensus estimate of $65.00 million by 7.29 percent. This is a 34.67 percent increase over sales of $44.75 million the same period last year.

Earnings

Earnings Misses

23andMe Holding Q3 2025 GAAP EPS From Cont Ops $(1.02), Sales $60.26M Miss $65.00M Estimate

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and setting the stage for a legal and political showdown over the congressional power of the purse that could heavily impact a <a href="https://www.benzinga.com/markets">wide range of industries.</a>
The directive, issued Monday by the Office of Management and Budget and received by several media outlets, requires all federal agencies to halt disbursements while programs are reviewed for alignment with President Donald Trump's policy priorities.
This includes halting new awards, existing payment and funding for projects until reviewed.
The exact financial impact of the order remains uncertain. Budget experts cited <a href="https://www.washingtonpost.com/business/2025/01/28/trump-spending-freeze-upends-washington-triggering-legal-threats-delays/">by the Washington Post </a>estimate at least tens of billions of dollars are at stake, though the White House directive suggests the total could be significantly higher.
Of the almost $10 trillion spent by the federal government in fiscal 2024, more than $3 trillion was federal financial assistance, Matthew Vaeth, acting director at the OMB, said in the memorandum.
&#8220;Financial assistance should be dedicated to advancing Administration priorities,&#8221; Vaeth said, adding that &#8220;the use of Federal resources to advance Marxist equity, transgenderism, and green new deal social engineering policies is a waste of taxpayer dollars that does not improve the day-to-day lives of those we serve.&#8221;
The White House said that Social Security and Medicare remain untouched. The sweeping pause threatens funding for universities, nonprofits, contractors and private companies that depend on federal assistance.
&#8220;Nothing in this memo should be construed to impact Medicare or Social Security benefits,&#8221; the memo said. 
The immediate focus will be on how agencies handle exemptions. The OMB memo allows federal departments to request case-by-case approvals, which means some funding may still flow, but the process is likely to be slow and politically charged.
Federal agencies have until Feb. 10, 2025, to provide OMB with detailed reports outlining which programs, projects, and activities are affected by the funding pause.
<h3 class="wp-block-heading">Legal, Political Showdown Over Federal Funds </h3>
The move is triggering legal challenges from nonprofits and Democratic-led states.
Within hours of the announcement, lawsuits were filed in federal courts in New York, Illinois and Oregon, arguing that Trump does not have the authority to withhold congressionally approved spending.
Senate Minority Leader Chuck Schumer was among the first to push back, saying Congress-approved investments are legally mandated and asserting the president lacks the authority to override the Impoundment Control Act of 1974, which restricts unilateral executive control over federal funds.
Trump has long argued that the 1974 law is unconstitutional, stating that past presidents had far more discretion over spending before its passage.
<h3 class="wp-block-heading">Which Industries Could Face Trouble?</h3>
Some of the hardest-hit sectors could include clean energy, defense, health care and education, where federal dollars have played a crucial role in driving investment and growth in recent years.
Trump's OMB memo explicitly targeted climate initiatives and green energy programs. Shares of solar and renewable energy companies were among the hardest hit following the federal funding freeze.
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) and the Invesco Wilderhill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) fell by 2% and 1.3%, respectively, on Tuesday. 
Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) dropped 12%, Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 9.2% and SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 5%. 
Defense contractors such as Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) may also see rising uncertainty. While military spending is unlikely to be cut outright, several defense contractors rely on federal grants for research and development. 
The impact on health care remains unclear. While Medicare is shielded, Medicaid funding — which supports hospitals, managed care providers and pharmaceutical companies — could be at risk.
HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) and Universal Health Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) fell by 1% and 1.4%, respectively, while Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) showed resilience Tuesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43281252/fed-set-to-signal-no-rush-to-cut-rates-as-wall-street-awaits-policy-clarity">Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity</a></li>
</ul>
Photo via Shutterstock.

Equities

Government

Large Cap

Regulations

Sector ETFs

Politics

Econ #s

Markets

Movers

ETFs

NOVA

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SEDG

Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care

LFUS

Littelfuse Expects Q1 FY25 Net Sales Of $520M - $550M (Est $540.992M), Adjusted EPS Of $1.70 - $1.90 (Est $2.11)

Stride Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) shares are trading higher in Tuesday&#8217;s after-hours session after the online education company reported better-than-expected quarterly results and<a href="https://www.benzinga.com/pressreleases/25/01/g43287471/stride-posts-record-quarterly-results"> issued strong guidance</a>.
What Happened: Stride reported fiscal second-quarter revenue of $587.2 million, beating analyst estimates of $569.25 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported quarterly earnings of $2.03 per share, beating analyst estimates of $1.94 per share. 
Income from operations totaled $125.1 million, up from $84.3 million in the prior year&#8217;s quarter. Adjusted EBITDA totaled $160.4 million, up from $118.3 million on a year-over-year basis.
Second-quarter enrollments averaged 230,600, up 19.4% year-over-year. Revenue per enrollment for the&nbsp;second quarter&nbsp;was&nbsp;$2,395,&nbsp;flat year-over-year. 
Stride said it ended the quarter with $738.1 million in cash, cash equivalents and marketable securities. 
Guidance: Stride expects third-quarter revenue to be in the range of $585 million to $600 million versus estimates of $571.86 million. The company sees full-year 2025 revenue of $2.32 billion to $2.36 billion versus estimates of $2.29 billion. 
Management will further discuss the company&#8217;s quarterly performance on a call with analysts and investors at 5 p.m. ET.
LRN Price Action: <a href="http://benzinga.com/quote/lrn">Stride shares</a> were up 3.62% at $125.01 in after-hours at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43288076/qorvo-stock-soars-after-strong-q3-results-details">Qorvo Stock Soars After Strong Q3 Results: Details</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Education

After-Hours Center

Stride Beats Analyst Estimates In Q2: Here's A Look At The Numbers

First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.51 by 3.92 percent. This is a 1.92 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $116.99 million which beat the analyst consensus estimate of $116.45 million by 0.47 percent. This is a 8.44 percent increase over sales of $107.89 million the same period last year.

Earnings Beats

BUSE

First Busey Q4 2024 Adj EPS $0.53 Beats $0.51 Estimate, Sales $116.99M Beat $116.45M Estimate

Ashland Continues To Expect FY25 Sales Of $1.90B - $2.05B (Est $1.963B) And Adjusted EBITDA Of $430M - $470M

CrossFirst Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.65 percent. This is a 15.38 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $68.87 million which beat the analyst consensus estimate of $67.50 million by 2.03 percent. This is a 12.10 percent increase over sales of $61.44 million the same period last year.

CrossFirst Bankshares Q4 2024 Adj EPS $0.45 Beats $0.43 Estimate, Sales $68.87M Beat $67.50M Estimate

Trading Halt: Halted at 5:10:00 p.m. ET - Trading Halt: Halt News Pending

Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.32 by 37.5 percent. This is a 12 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $72.16 million which beat the analyst consensus estimate of $62.45 million by 15.55 percent. This is a 246.31 percent increase over sales of $20.84 million the same period last year.

ALRS

Alerus Finl Q4 2024 Adj EPS $0.44 Beats $0.32 Estimate, Sales $72.16M Beat $62.45M Estimate

Electric vehicle company Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is likely to put an emphasis on future new models and technology progress for autonomous vehicles when the company reports fourth-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a>
Earnings Estimates: Analysts expect Tesla to report fourth-quarter revenue of $27.13 billion, up from $25.17 billion in last year's fourth quarter, according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012825&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company has missed analyst revenue estimates in four of the last five quarters and six of the last 10 quarters overall.
Analysts expect Tesla to report fourth quarter earnings per share of 74 cents, up from 71 cents per share in last year's fourth quarter. The company has missed analyst earnings per share estimates in four of the last five quarters.
Tesla <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on">previously announced </a>its fourth-quarter vehicle production and delivery figures. The company produced 459,445 vehicles and delivered 495,570 vehicles in the quarter. While the deliveries were a record in the fourth quarter, the company's 1.79 million vehicles delivered in 2024 marked a year-over-year decline from 1.81 million in 2023. This was the first annual deliveries decline in company history.
Read Also:<a href="https://www.benzinga.com/news/25/01/42986863/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestsel"> US Electric Vehicle Sales Hit Record 1.3 Million Units In 2024, Despite Tesla Declines: Top 10 Bestselling Models</a>
What Analysts Are Saying: Analysts were mixed<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year"> on the short-term outlook</a> for Tesla after the company's fourth-quarter delivery report. They continue to show questions for the short term with many bullish outlooks on the EV stock for the long term.
Goldman Sachs analyst Mark Delaney <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43246903/tesla-analysts-top-5-items-to-watch-in-q4-earnings-will-refreshed-model-y-new-evs-help-growth">recently highlighted</a> the Model Y update, automotive market share and a consumer survey in a new investor note.
The analyst maintained a Neutral rating with a price target of $345.
&#8220;Mix and how fast Tesla ramps up production of the refreshed version will help determine the effect on blended ASPs. We believe the new version offers several good enhancements," Delaney said of the Model Y refresh.
Ahead of Tesla&#8217;s fourth-quarter financial results, Delaney highlighted five of the top items to watch.
<ol start="1">
<li>Automotive non-GAAP gross margins</li>
<li>Vehicle delivery outlook for 2025</li>
<li>Progress with FSD and AI-related efforts</li>
<li>Growth in other segments, including Services and Energy</li>
<li>Progress with Optimus and expectations on ramp timing</li>
</ol>
&#8220;We believe a key debate in the market will be whether Tesla can grow more meaningfully in 2025/2026, driven by a refreshed Model Y and a new lower-cost model or models,&#8221; Delaney added.
Morgan Stanley analysts said <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43259982/tesla-earnings-delivery-outlook-model-y-ramp-up-optimus-bot-in-focus-say-analysts">the key topic </a>for Tesla's earnings report and conference call will be if the company is sticking with a delivery growth target of 20% to 30% for 2025. The analysts said growth of 10% to 20% is more likely with pressures on the EV market, increased competition for the sector in China and the potential of federal tax credits going away.
The analysts said production ramp-up of the Model Y refresh, FSD progress and any updates on the Optimus humanoid bot will also be key topics to watch.
Morgan Stanley has an Overweight rating on Tesla and $430 price target.
On the other side of the bull case for Tesla is Bank of America analyst John Murphy who <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42856115/tesla-analyst-on-high-stakes-future-optimus-robotaxi-fsd-have-potential-but-execution-risks-loom">downgraded Tesla</a> from Buy to Neutral earlier this month and raised the price target from $400 to $490.
Murphy shared a Tesla sum-of-the-parts valuation and what could have the highest impact on the future of the company.
Tesla has long-term catalysts, but the rise in the stock price in 2024 could put valuation into question, Murphy said in the note. &#8220;Valuation captures much of long-term potential from autos, robotaxi, other and execution risk is high.&#8221; 
Murphy added that there is still upside to Tesla stock, but the price increase limits the long-term potential.
Tesla&#8217;s robotaxi segment is called the biggest opportunity by Murphy, a segment that he believes could account for nearly 50% of the company&#8217;s valuation and be worth $420 billion in the U.S. and over $800 billion globally in the future.
Key Items to Watch: Delivery guidance for 2025 remains the biggest item for most analysts and investors. Outside of that there are multiple areas that people will be watching Thursday.
This includes the potential end of the $7,500 federal tax credit for EVs. Tesla CEO Elon Musk, who supported Donald Trump in the 2024 election, has supported this potential end as it could be good for his company and bad for competitors.
Analysts may try to get Musk to comment on the timing of the end of the credit and if it could lead to a short-term demand spike.
As a close ally of Trump, another topic could be autonomous vehicle testing on roads. Trump <a href="https://www.benzinga.com/general/politics/24/10/41298125/maybe-musk-missed-the-memo-trumps-plan-to-ban-autonomous-vehicles-could-sour-friendship">previously said he </a>would ban autonomous vehicles from roads, which could cause harm to Tesla. An update on where things stand would likely be well received by investors if Trump has reversed his stance.
With the promise of new models in 2025, investors and analysts will also be looking for commentary on the timing of this and any hints at what this means.
TSLA Price Action: Tesla stock is down 0.3% Wednesday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 108% over the last year, with the majority of gains coming after Trump won the election.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a></li>
</ul>
Photo created using artificial intelligence via MidJourney.

Analyst Color

Previews

Reiteration

Trading Ideas

TSLA

Tesla Q4 Earnings Preview: 2025 Delivery Growth, FSD, Model Y Refresh, New Vehicles Among Key Topics

Provident Finl Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFS#NYSE">PFS</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.47 by 21.28 percent. This is a 2.78 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $181.74 million which missed the analyst consensus estimate of $184.78 million by 1.65 percent. This is a 89.73 percent increase over sales of $95.79 million the same period last year.

Provident Finl Servs Q4 2024 GAAP EPS $0.37 Misses $0.47 Estimate, Sales $181.74M Miss $184.78M Estimate

Macro Economic Events

Macro Notification

Economics

General

USA API Weekly Crude Oil Stock 2.860M Barrel Build Vs 3.700M Barrel Build Est.; 1.000M Barrel Build Prior

Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.18 by 55.56 percent. This is a 37.78 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $405.00 million which missed the analyst consensus estimate of $428.92 million by 5.58 percent. This is a 14.38 percent decrease over sales of $473.00 million the same period last year.

Ashland Q1 2025 Adj EPS $0.28 Beats $0.18 Estimate, Sales $405.00M Miss $428.92M Estimate

First Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) reported quarterly earnings of $0.35 per share which met the analyst consensus estimate. This is a 20.45 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $120.77 million which beat the analyst consensus estimate of $119.68 million by 0.91 percent. This is a 0.35 percent increase over sales of $120.35 million the same period last year.

First Commonwealth Q4 Adj $0.35, Inline, Sales $120.77M Beat $119.68M Estimate

Across the recent three months, 6 analysts have shared their insights on Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ecolab, revealing an average target of $285.0, a high estimate of $300.00, and a low estimate of $270.00. Surpassing the previous average price target of $281.50, the current average has increased by 1.24%.
<img src="https://www.benzinga.com/files/images/story/2025/1738101698_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ecolab. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$306.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$276.00</td>
<td>$276.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ecolab. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ecolab compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ecolab's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ecolab's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ECL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ecolab analyst ratings.</a>
<h2>Delving into Ecolab's Background</h2>
Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.
<h3>Financial Insights: Ecolab</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ecolab's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.02%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ecolab's net margin excels beyond industry benchmarks, reaching 18.42%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ecolab's ROE excels beyond industry benchmarks, reaching 8.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ecolab's ROA excels beyond industry benchmarks, reaching 3.38%. This signifies efficient management of assets and strong financial health.
Debt Management: Ecolab's debt-to-equity ratio is below the industry average. With a ratio of 0.97, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Ecolab: What You Need To Know

Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Celestica, revealing an average target of $101.6, a high estimate of $115.00, and a low estimate of $91.00. Observing a 41.76% increase, the current average has risen from the previous average price target of $71.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1738101689_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Celestica among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Chan</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Paul Treiber</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Celestica. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Celestica compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Celestica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celestica's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celestica analyst ratings.</a>
<h2>Unveiling the Story Behind Celestica</h2>
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.
<h3>Breaking Down Celestica's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Celestica's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 22.33%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Celestica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.67% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Celestica's ROE stands out, surpassing industry averages. With an impressive ROE of 5.06%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Celestica's ROA stands out, surpassing industry averages. With an impressive ROA of 1.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Azure Power Global

Azure Power Global (AZREF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga